

WEST Search History

DATE: Monday, August 01, 2005

Hide? Set
Name Query


DB=PGPB,USPT,EPAB; PLUR=YES; OP=ADJ

- ☐ L39 L38 and (apoptosis or (cell death))
- ☐ L38 l37 and l2
- ☐ L37 L36 and l26
- ☐ L36 L35 or l34
- ☐ L35 (424/94.61)! [CCLS]
- ☐ L34 (514/12,45,663)! [CCLS]
- ☐ L33 L32 and calcium
- ☐ L32 L31 and L1
- ☐ L31 L30 and L2
- ☐ L30 L29 or L28
- ☐ L29 ("5527527"|"5527778"|"5578599"|"5604198"|"5670477"|"5677344"|"5679706"|"5686416"
- ☐ L28 ("5112596"|"5124146"|"5215985"|"5256688"|"5262419"|"5314887"|"5399587"|"5416097"
- ☐ L27 L26 and L2
- ☐ L26 L25 or L24
- ☐ L25 ns-1619
- ☐ L24 L23 or L22
- ☐ L23 ns1619
- ☐ L22 ns 1619
- ☐ L21 L20 and L19
- ☐ L20 cromakalim
- ☐ L19 L18 and L14
- ☐ L18 L17 and L7
- ☐ L17 = 2001
- ☐ L16 L14 and L9
- ☐ L15 L14 and L6
- ☐ L14 calcium with L1
- ☐ L13 L12 and L6
- ☐ L12 L11 or L10
- ☐ L11 ningaraj.in.
- ☐ L10 black.in.

- ☐ L9 L8 and L7
- ☐ L8 @AY >= 2001
- ☐ L7 L6 and L2
- ☐ L6 L5 or L4 or L3
- ☐ L5 L1.clm.
- ☐ L4 L1.ab.
- ☐ L3 L1.ti.
- ☐ L2 cancer\$ or tumor\$ or neoplas\$ or apoptosis or (cell proliferation or cellular proliferation) o
- ☐ L1 potassium channel

END OF SEARCH HISTORY

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 153587-01-0 REGISTRY
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-
 5-(trifluoromethyl)- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN **NS 1619**
 FS 3D CONCORD
 MF C15 H8 F6 N2 O2
 SR CA
 LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS,
 CHEMCATS, CSCHM, EMBASE, IMSDRUGNEWS, IMSRESEARCH, MEDLINE, PHAR,
 PROMT, PROUSDDR, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
 (Properties); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

61 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 61 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ACCESSION NUMBER: 1999:305307 CAPLUS
DOCUMENT NUMBER: 131:128233
TITLE: Potassium channels and neurodegenerative diseases
AUTHOR(S): Rundfeldt, Chris
CORPORATE SOURCE: Dept. of Pharmacology I, Corporate R and D, ASTA
Medica GmbH, Radebeul, D-01445, Germany
SOURCE: Drug News & Perspectives (1999), 12(2), 99-104
CODEN: DNPEED; ISSN: 0214-0934
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 43

THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB A review, with 43 refs. Many different insults and mechanisms can lead to neurodegeneration. Potassium channel openers may play a role in counteracting or preventing this damage. A heterogeneous array of potassium channels, classified according to their electrophysiol. properties, has been identified. Different potassium channels are involved in several steps within the pathophysiol. cascade that ultimately leads to **cell death**; therefore, several potassium channel openers may interfere with different steps within the neurodegenerative cascade. However, it is possible that in case of severe insults potassium channel opening may not lead to neuroprotection, due to the fact that potassium channels are already endogenously activated and the extracellular potassium concentration is already very high. Thus, further channel opening may have no addnl. pos. effects. Selective drugs for individual channel subtypes should be used in predictive models of neurodegeneration; however, the currently known potassium channel openers are few and nonselective. The classes of drugs that need to be explored include potassium channel openers of the ATP-sensitive, high-conductance calcium-sensitive, and inward rectifier or leakage types. Selective openers for inward rectifier potassium channels are currently not available, although activation of 5-HT_{1A} receptors results in the induction of an inwardly rectifying potassium current. Potent neuroprotective properties have been described for different 5-HT_{1A} agonists in models of focal and global ischemia. Retigabine, a leakage-current potassium channel opener, has been shown to have neuroprotective effects in animal models of neurodegeneration. Of the currently available potassium channel openers, retigabine and BAY-X-3702 are active at nontoxic doses. Further research is needed to develop selective, well-tolerated potassium channel openers.

IT 94470-67-4, Cromakalim 141797-92-4, NS 004 144980-77-8, BAY-X-3702
150812-12-7, Retigabine **153587-01-0**, NS-1619 184653-84-7,
SB-204269

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(potassium channels, potassium channel openers and neurodegenerative diseases)

ACCESSION NUMBER: 2001078709 PCTFULL ED 20020826
 TITLE (ENGLISH): TREATMENT OF NEURODEGENERATIVE DISEASE
 TITLE (FRENCH): TRAITEMENT DES MALADIES NEURODEGENERATIVES
 INVENTOR(S): BAMDAD, R., Shoshanna;
 BAMDAD, Cynthia, C.
 PATENT ASSIGNEE(S): MINERVA BIOTECHNOLOGIES CORPORATION
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 2001078709	A2	20011025
---------------	----	----------

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
 IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
 MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
 TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
 CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:

PRIORITY INFO.:

WO 2001-US12484	A	20010412
US 2000-60/196,497		20000412
US 2000-60/214,221		20000623
US 2000-60/248,890		20001115